Abstract
While many drugs have some effect on serotonergic receptors this chapter focuses upon the toxicity seen with medications whose primary antidepressant therapeutic mechanism of action is to modify serotoninergic transmission. This includes selective serotonin reuptake inhibitors (SSRI), serotonin noradrenergic reuptake inhibitors (SNRI), and tetracyclic and triazolopyridine antidepressants (Tables 1, 2, 3, and 4).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev. 1992;72(1):165–229.
Wang H, Goehring A, Wang KH, Penmatsa A, Ressler R, Gouaux E. Structural basis for action by diverse antidepressants on biogenic amine transporters. Nature. 2013;503(7474):141–5.
Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355(9207):911–8.
Buckley NA, Whyte IM, Dawson AH, Isbister GK. A prospective cohort study of trends in self-poisoning, newcastle, australia, 1987–2012: Plus ça change, plus c'est la même chose. Med J Aust. 2015;202(8):438–42.
Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd annual report. Clin Toxicol (Phila). 2015;53(10):962–1147.
Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of united kingdom mortality data. BMJ. 2002;325(7376):1332–3.
Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, Kapur N. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry. 2010;196(5):354–8.
Koski A, Vuori E, Ojanperä I. Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on finnish postmortem data. Int J Leg Med. 2005;119(6):344–8.
Whyte I. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;96(5):369–74.
Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85(1):11–28.
Fujishiro J, Imanishi T, Onozawa K, Tsushima M. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol. 2002;454(2):183–8.
White NC, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol. 2008;4(4):238–50.
Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, et al. Drug-induced long QT syndrome: HERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol. 2006;149(5):481–9.
Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (ssris) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277–85.
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348:g1626.
Friberg LE, Isbister GK, Hackett LP, Duffull SB. The population pharmacokinetics of citalopram after deliberate self-poisoning: a bayesian approach. J Pharmacokinet Pharmacodyn. 2005;32(3–4):571–605.
Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol. 2006;61(2):177–90.
Isbister GK, Friberg LE, Duffull SB. Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med. 2006;32(7):1060–5.
van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med. 2009;54(3):404–8.
van Gorp F, Duffull S, Hackett LP, Isbister GK. Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. Br J Clin Pharmacol. 2012;73(3):402–10.
Hayes BD, Klein-Schwartz W, Clark RF, Muller AA, Miloradovich JE. Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med. 2010;39(1):44–8.
Isbister GK, Friberg LE, Stokes B, Buckley NA, Lee C, Gunja N, et al. Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med. 2007;50(5):593–600, 600.e1–46.
Tarabar AF, Hoffman RS, Nelson LS. Citalopram overdose: late presentation of torsades de pointes (tdp) with cardiac arrest. J Med Toxicol. 2008;4(2):101–5.
Kanjanauthai S, Kanluen T, Chareonthaitawee P. Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol. 2008;131(1):e33–4.
White S, Rumack B. The acetaminophen toxicity equations: “solutions” for acetaminophen toxicity based on the rumack-matthew nomogram. Ann Emerg Med. 2005;45(5):563–4.
Chan A, Isbister G, Kirkpatrick C, Dufful S. QJM drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM. 2007;100(10):609–15.
Waring WS, Graham A, Gray J, Wilson AD, Howell C, Bateman DN. Evaluation of a QT nomogram for risk assessment after antidepressant overdose. Br J Clin Pharmacol. 2010;70(6):881–5.
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–42.
Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. British journal of clinical pharmacology. 2016;81(3):420–7.
Kumar VV, Oscarsson S, Friberg LE, Isbister GK, Hackett LP, Duffull SB. The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose. Clin Pharmacol Ther. 2009;86(4):403–10.
Chan AN, Gunja N, Ryan CJ. A comparison of venlafaxine and ssris in deliberate self-poisoning. J Med Toxicol. 2010;6(2):116–21.
Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;96(5):369–74.
Wang S-Y, Calderon J, Wang GK. Block of neuronal na + channels by antidepressant duloxetine in a state-dependent manner. J Am Soc Anesthesiol. 2010;113(3):655–65.
Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1999;291(1):280–4.
Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007;64(2):192–7.
Batista M, Dugernier T, Simon M, Haufroid V, Capron A, Fonseca S, et al. The spectrum of acute heart failure after venlafaxine overdose. Clin Toxicol (Phila). 2013;51(2):92–5.
Neil CJ, Chong CR, Nguyen TH, Horowitz JD. Occurrence of tako-tsubo cardiomyopathy in association with ingestion of serotonin/noradrenaline reuptake inhibitors. Heart Lung Circ. 2012;21(4):203–5.
Christoph M, Ebner B, Stolte D, Ibrahim K, Kolschmann S, Strasser RH, Schön S. Broken heart syndrome: Tako tsubo cardiomyopathy associated with an overdose of the serotonin-norepinephrine reuptake inhibitor venlafaxine. Eur Neuropsychopharmacol. 2010;20(8):594–7.
Francino MC, Bretaudeau Deguigne M, Badin J, Turcant A, Perrotin D. Hypoglycaemia: a little known effect of venlafaxine overdose. Clin Toxicol (Phila). 2012;50(3):215–7.
Jacob J, Albert D, Heard K. Single-agent duloxetine ingestions. Hum Exp Toxicol. 2013;32(4):427–33.
Just S, Gros S, Reichert C, Heistermann E, Hofmann- Walbeck P, Stedtler U, et al. Duloxetine overdose: a case series Clinical Toxicology. 2015;53(4):387.
Höjer J, Hulting J, Salmonson H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila). 2008;46(4):336–7.
Bosse GM, Spiller HA, Collins AM. A fatal case of venlafaxine overdose. J Med Toxicol. 2008;4(1):18–20.
Wilson AD, Howell C, Waring WS. Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series. J Toxicol Sci. 2007;32(1):97–101.
Holliday SM, Benfield P. Venlafaxine. Drugs. 1995;49(2):280–94.
Kumar VV, Isbister GK, Duffull SB. The effect of decontamination procedures on the pharmacodynamics of venlafaxine in overdose. Br J Clin Pharmacol. 2011;72(1):125–32.
Isbister GK. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol. 2009;9999(999A):572–6.
Vinetti M, Haufroid V, Capron A, Classen J-FO, Marchandise S, Hantson P. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. Clin Toxicol (Phila). 2011;49(9):865–9.
Hjer J, Hulting J, Salmonson H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila). 2008;46(4):336–7.
Samuelov-Kinori L, Kinori M, Kogan Y, Swartzon M, Shalev H, Guy D, et al. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes? J Electrocardiol. 2009;42(4):353–7.
Combes A, Peytavin G, Théron D. Conduction disturbances associated with venlafaxine. Ann Intern Med. 2001;134(2):166.
Shah AS, Eddleston M. Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures? Clinical Toxicology. 2010;48(8):800–5.
Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol Clin Exp. 2006;21(2):117–25.
Timmer CJ, Sitsen JMA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38(6):461–74.
Berling I, Isbister GK. Mirtazapine overdose is unlikely to cause major toxicity. Clin Toxicol. 2014;52(1):20–4.
LoVecchio F, Riley B, Pizon A, Brown M. Outcomes after isolated mirtazapine (remeront) supratherapeutic ingestions. J Emerg Med. 2008;34(1):77–8.
Stephen Waring W, Good AM, Nicholas Bateman D. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol (Phila). 2007;45(1):45–50.
Schaper A, Farber E, Ebbecke M, Desel H. Suicide with mirtazapine-hardly possible. J Toxicol Clin Toxicol. 2002;40(3):343–4.
Koseoglu Z, Kara B, Satar S. Bradycardia and hypotension in mianserin intoxication. Human & experimental toxicology. 2010; 29(10):887–8.
Haefeli WE, Schoenenberger RA, Scholer A. Recurrent ventricular fibrillation in mianserin intoxication. BMJ Br Med J. 1991;302(6773):415.
Hla KK, Boyd O. Mianserin and complete heart block. Hum Exp Toxicol. 1987;6(5):401–2.
Chand S, Crome P, Dawling S. One hundred cases of acute intoxication with mianserin hydrochloride. Pharmacopsychiatry. 1981;14(01):15–7.
Shaw WL. The comparative safety of mianserin in overdose. Curr Med Res Opin. 1980;6 Suppl 7:44–51.
Inman WW. Blood disorders and suicide in patients taking mianserin or amitriptyline. Lancet. 1988;332(8602):90–2.
Brogden RN, Heel RC, Speight TM, Avery GS. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs. 1981;21(6):401–29.
Haria M, Fitton A, McTavish D. Trazodone. Drugs Aging. 1994;4(4):331–55.
Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34 Suppl 1:D668–72.
Buckley DNA, McManus PR. Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 2012;18(5):369–81.
Rhyee SH, Farrugia L, Campleman SL, Wax PM, Brent J, Toxicology Investigators Consortium. The toxicology investigators consortium case registry – the 2014 experience. J Med Toxicol. 2015;11(4):388–409.
Henry JA, Ali CJ. Trazodone overdosage: experience from a poisons information service. Hum Exp Toxicol. 1983;2(2):353–6.
Chung KJ, Wang YC, Liu BM, Supernaw RB. Management of ventricular dysrhythmia secondary to trazodone overdose. J Emerg Med. 2008;35(2):171–4.
Service JA, Waring WS. QT prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila). 2008;46(1):71–3.
Perry R, Cassagnol M. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009;31(Pt 1):1374–404.
Deepak P, Kumar TN. Duloxetine-pharmacological aspects. Int J Biol Med Res. 2011;2(2):589–92.
Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine. Clin Pharmacokinet. 2011;50(5):281–94.
Shami M, Elliott HL, Kelman AW, Whiting B. The pharmacokinetics of mianserin. Br J Clin Pharmacol. 1983;15(S2):313S–22.
Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:349–54.
Areberg J, Søgaard B, Højer AM. The clinical pharmacokinetics of lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol. 2012;111(3):198–205.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd Edition
-
I
Evidence obtained from at least one properly randomized controlled trial.
-
II-1
Evidence obtained from well-designed controlled trials without randomization.
-
II-2
Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.
-
II-3
Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.
-
III
Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees.
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this entry
Cite this entry
Dawson, A.H. (2017). Serotonergic Antidepressants. In: Brent, J., et al. Critical Care Toxicology. Springer, Cham. https://doi.org/10.1007/978-3-319-17900-1_36
Download citation
DOI: https://doi.org/10.1007/978-3-319-17900-1_36
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-17899-8
Online ISBN: 978-3-319-17900-1
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences